Suzhou Ribo Life Science, a company focused on small interfering RNA drugs, raised $39 million in a B round led by China’s State Development and Investment Corporation. Founded in 2007, Ribo is developing siRNA drugs for hepatitis B, hyperlipidaemia and liver cancer. In 2012, Ribo formed a China JV with US-based Quark Pharma, also a siRNA company. Three years later, the CFDA approved the JV’s Ischemic Optic Neuropathy siRNA drug for use in China.
